Flixotide Evohaler 125mcg 120 dose

Flixotide Evohaler. Therapeutic indicationsFluticasone propionate given by inhalation offers prophylactic treatment for asthma.Adults:Mild asthma: Patients requiring intermittent symptomatic bronchodilator asthma medication on a regular daily basis. Moderate asthma: Patients with unstable or worsening asthma despite prophylactic therapy or bronchodilator alone. Severe asthma: Patients with severe chronic asthma and those who are dependent on systemic corticosteroids for adequate control of symptoms. On introduction of inhaled fluticasone propionate many of these patients may be able to reduce significantly, or to eliminate, their requirement for oral corticosteroids. Children:Any child who requires prophylactic medication, including patients not controlled on currently available prophylactic medication. Posology and method of administrationPatients should be made aware of the prophylactic nature of therapy with inhaled fluticasone propionate and that it should be taken regularly even when they are asymptomatic. If patients find that relief with short-acting bronchodilator treatment becomes less effective or they need more inhalations than usual, medical attention must be sought. Flixotide Evohaler is for oral inhalation use only. Flixotide Evohaler may be used with a Volumatic spacer device by patients who find it difficult to synchronise aerosol actuation with inspiration of breath. The onset of therapeutic effect is within 4 to 7 days. Adults and children over 16 years: 100 to 1,000 micrograms twice daily, usually as two twice daily inhalations. Prescribers should be aware that fluticasone propionate is as effective as other inhaled steroids approximately at half the microgram daily dose. For example, a 100mcg of fluticasone propionate is approximately equivalent to 200mcg dose of beclometasone dipropionate (CFC containing) or budesonide. Due to the risk of systemic effects, doses above 500 micrograms twice daily should be prescribed only for adult patients with severe asthma where additional clinical benefit is expected, demonstrated by either an improvement in pulmonary function and/or symptom control, or by a reduction in oral corticosteroid therapy (see 4.4 Special Warnings and Precautions for Use and 4.8 Undesirable Effects). Patients should be given a starting dose of inhaled fluticasone propionate which is appropriate to the severity of their disease. The dose may be increased until control is achieved or reduced to the minimum effective dose, according to the individual response. For full data sheet go to: https://www.medicines.org.uk/emc/product/7601/smpc